Light Transmission Aggregometry
in platelet rich plasma
LTA is considered to be the ‘gold standard’ for in vitro platelet function testing and is usually expected by regulatory authorities if any platelet testing is required in a drug development programme. We are experts in assessing platelet aggregation by LTA and will design a study protocol that is specific and sensitive to assess the effects of your candidate compound on platelet function.
This technique is based on measuring the light transmitted through a sample of platelet rich plasma (PRP), placed between a light source and a photocell. The platelet suspension allows relatively little light to pass through. The addition of an agonist causes platelet aggregation so the sample becomes clearer and more light is transmitted to the detector; readings are recorded as a function of time.
Acyl derivatives of coenzyme A inhibit platelet function via antagonism at P2Y1 and P2Y12 receptors: A new finding that may influence the design of anti-thrombotic agents. Platelets, 19(2): 134-145.
DG-041 inhibits the EP3 prostanoid receptor—A new target for inhibition of platelet function in atherothrombotic disease. Platelets, 19(8): 605-613.
Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. European Heart Journal, 27(9): 1038-1047.
How does measurement of platelet P-selectin compare with other methods of measuring platelet function as a means of determining the effectiveness of antiplatelet therapy? Platelets, 30(3): 290-295.